<table style='width:50%' cellspacing='10'><tr><td>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1198983</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 59705</a></font><br>
<font size='4'>Mr NAME is a AGE_40s year old with metastatic stage IV breast cancer who is here for cycle one , day eight of treatment on protocol TRIAL_12_030 with GDC 0980 , a PI3 kinase/MTOR inhibitor
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1519000</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 1173185</a></font><br>
<font size='4'>Foundation Medicine testing was submitted of a breast tumor specimen on DATE_2014 and her tumor was found to harbor the following genomic alterations : PIK3CA N345Y , FGFR1 amplification , RB 1 loss of exons 7 11 , as well as aberrations in T P_53 , NFKB1A , and VNF703
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1203739</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 174077</a></font><br>
<font size='4'>A AGE_40s year old woman with stage IV breast cancer expressing a PI3 kinase mutation , and being treated on investigational study TRIAL_12_030 , GDC0980
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1195292</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 617095</a></font><br>
<font size='4'>A AGE_40s year old woman with stage IV breast cancer and a PI3 kinase mutation
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1198383</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 506944</a></font><br>
<font size='4'>NAME is a AGE_40s year old woman with stage IV breast cancer metastatic to bone and liver who presents today for cycle #1 , day #8 , of therapy with GDC 0980 , a PI3 kinase/mTOR inhibitor on protocol TRIAL_12_030
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 2173751</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 581056</a></font><br>
<font size='4'>Again , AKT is a molecule of PI3 kinase pathway that is an inhibition that is thought to be effective in breast cancers that have progressed through trastuzumab therapy
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1792186</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 859045</a></font><br>
<font size='4'>Temsirolimus is an mTOR inhibitor and aberrations of the Pi3K pathway with activation of the Pi3 kinase or loss of P_10 have been implicated in triple negative breast cancer
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1192510</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 63814</a></font><br>
<font size='4'>This is a AGE_40s year old woman with metastatic breast cancer with a PIK3CA mutation , currently on protocol TRIAL_12_030
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1572545</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 270408</a></font><br>
<font size='4'>The PI3 kinase pathway is often dysregulated in triple negative breast cancer , and EGFR over expression is seen in 20% to 30% of patients with triple negative breast cancer
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1192532</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 862674</a></font><br>
<font size='4'>This is a AGE_40s year old woman with metastatic breast cancer , currently on an investigational PI3K inhibitor
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1954654</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 986183</a></font><br>
<font size='4'>currently open but expected to open in the next several months for ER positive metastatic breast cancer involving Faslodex in conjunction with a PI3 kinase inhibitor
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1197159</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 494171</a></font><br>
<font size='4'>The patient is a AGE_40s year old woman with breast cancer metastatic to bone and liver , who is referred by Dr NAME for consideration of treatment on protocol TRIAL_12_030 with GDC 0980 , a PI3 kinase/mTOR inhibitor
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1137646</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 1144252</a></font><br>
<font size='4'>I explained that the current study is enrolling to an expansion cohort of patients with breast cancer who have tumors with PI3 kinase mutations
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 1853296</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 1007541</a></font><br>
<font size='4'>We explained that we would prioritize a trial , particularly protocol TRIAL_12_107 evaluating the combination of a MEK inhibitor and a PI3 kinase inhibitor with a subset of patients with triple negative breast cancer
.</font><p>
<font size='5'><a href='http://0.0.0.0:8000/tracks/' target="_blank">Note 855925</a>&nbsp;<a href='http://0.0.0.0:8000/tracks/' target="_blank">Patient 1143159</a></font><br>
<font size='4'>In particular , she discussed that we are now assessing other pathways which are implicated in the growth of metastatic ER positive breast cancer , in particular , the PI3 kinase pathway
.</font><p>
</td></tr></table>

